Global experience with PSMA-based alpha therapy in prostate cancer

Area of Science:

• Oncology
• Radiopharmaceutical Therapy
• Medical Physics

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge.
• Novel therapeutic strategies are urgently needed to improve patient outcomes.
• Prostate-specific membrane antigen (PSMA) is a validated target in prostate cancer.

Purpose of the Study:

• To review the current state of PSMA-based alpha therapy (PAT) for mCRPC.
• To foster collaboration between basic scientists and physician-scientists.
• To advance the field of targeted alpha therapy.

Main Methods:

• Comprehensive literature review of existing PAT strategies.
• Discussion of treatment selection, outcomes, and toxicity.
• Identification of key questions for future research.

Main Results:

• PAT utilizes unique mechanisms of action, offering potential advantages over conventional therapies.
• Significant excitement surrounds the therapeutic potential of PSMA-targeted alpha emitters.
• Current research focuses on optimizing treatment protocols and understanding efficacy.

Conclusions:

• A deeper understanding of PAT's strengths and limitations is crucial for effective mCRPC treatment.
• PAT offers a promising avenue for developing rational combinatorial therapies.
• Targeting distinct tumor pathways with PAT may enhance treatment efficacy.